<DOC>
	<DOCNO>NCT00943306</DOCNO>
	<brief_summary>This long term follow study ass continue long term safety efficacy lomitapide patient homozygous familial hypercholesterolemia .</brief_summary>
	<brief_title>Long Term , Follow-on Study Lomitapide Patients With Homozygous Familial Hypercholesterolemia</brief_title>
	<detailed_description>This phase III open label clinical trial evaluate long-term efficacy safety lomitapide maximum tolerate dose ( patient ) establish clinical trial 733-005/UP1002 . Subjects complete study 733-005/UP1002 meet stop criterion eligible participate 733-012 . The treatment period continue decision make local competent authority regard marketing authorization . Lomitapide give orally daily . Patient specific dos carry forward 733-005/UP1002 , exceed maximum tolerate dose patient receive 733-005 /UP1002 . The maximum dose patient 80 mg/day . There reference therapy trial . The effect study drug compare baseline data ( 733-005/UP1002 ) . Concomitant lipid-lowering therapy include plasmapheresis LDL apheresis permit .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>1 . Completed UP1002 733005 . 2 . Willing able provide consent comply requirement study protocol . 1 . Met stop rule study discontinuation final visit study UP1002 733005 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Homozygous</keyword>
	<keyword>Familial</keyword>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>MTP</keyword>
	<keyword>Apheresis</keyword>
	<keyword>lomitapide</keyword>
	<keyword>Homozygous Familial Hypercholesterolemia ( HoFH )</keyword>
</DOC>